Please login to the form below

Not currently logged in
Email:
Password:

Boehringer appoints Paul Fonteyne to lead US operations

He takes over from J Martin Carroll as president and CEO of Boehringer Ingelheim USA

Boehringer Ingelheim US CEO Paul FonteyneBoehringer Ingelheim has promoted Paul Fonteyne to president and CEO of its US operations.

He takes over from J Martin Carroll, who will remain with the company in a corporate strategy and development role.

"Change is a necessary and healthy part of any successful company," said Carroll. "After nine years as president and CEO, it was time to let others take the lead on the day-to-day management of the company's US operations.

“I have worked with Paul for more than 15 years, and am confident that his depth and breadth of experience, combined with his passion for finding new ways to bring medicines to patients makes him well-suited to take on this role and help lead the company to even greater success.”

Fonteyne was formerly corporate senior vice president with responsibility for leading the global marketing strategy supporting Boehringer's prescription medicines business.

"I am excited to be given the opportunity to lead the US operations," said Fonteyne. "I believe this company is stronger now than at any point in its 126 year history.

“I look forward to working with my colleagues in the US and globally to bring the best ideas to bear so that we may continue delivering on our commitment to bring more health to patients and their families."

25th January 2012

Share

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Create Health

A specialist Advertising and Med Comms agency dedicated to bringing much-needed creativity to healthcare marketing. We believe that brilliant ideas...

Latest intelligence

Virtual Steering Committee & Peer Influence Program
In this customer story, we describe the methodology and results of our client’s ongoing Virtual Steering Committee & Peer Influence program....
Meeting healthcare’s rising challenges
The journey to discover novel therapies through digital innovation and ensure scientific advances achieve their potential...
Report gives insights to address gaps in HCP engagement
How does Pharma-HCP engagement need to evolve in today's digital landscape?...